The Prix Galien USA Awards are now open to medical device products, biotechnology, and pharmaceuticals. The award body, established in 1970 by French pharmacist Roland Mehl, recognizes “innovative medicines and medical technologies.”
The current round of awards will be open until May 31. Awards will be given at the Galien Forum and Prix Galien USA Ceremony Oct. 26 in New York City.
In order to be eligible, products or pharmaceuticals must have full FDA approval. They must also have attained marketing approval in the United States by Dec. 31, 2016. Products which received marketing approval more than five years before Dec. 31, 2016 are not eligible, as they are no longer considered “new and innovative.” Exceptions may be made to the five-year limit if the product has a sufficient “new and innovative indication” added within the last five years.
All entries will be presented in the 2017 Program Book, receive industry press publicity, receive a nominee certificate, and be part of additional publicity including an online video. The finalists will also be part of a special publication distributed to institutions and leading indexing services.
One to three products will be given awards in each of the following categories: Best Pharmaceutical Agent, Best Biotechnology Product, and Best Medical Technology.
Submission pricing and more detailed information can be found at the Prix Galien Award website here.